MenB Vaccine and UK Teenagers: Why the Gap in Protection and What Should Change

MenB Outbreak in Kent Raises Urgent Questions About Teen Vaccination

A confirmed outbreak of Meningitis B in Kent has thrown a spotlight on a troubling gap in the UK's vaccination programme — one that leaves teenagers and university students without protection against one of the most dangerous strains of bacterial meningitis.

Two young people have died in Canterbury, and further students remain hospitalised. Health authorities have confirmed that Meningitis B, or MenB, is the strain responsible — a bacterium capable of causing blood poisoning, sepsis, and life-threatening brain damage.

Why Haven't Older Teens Been Vaccinated Against MenB?

The UK introduced the MenB vaccine into its routine infant immunisation schedule back in 2015. Babies born from that point onwards have received the jab as standard. However, the current generation of older teenagers and university students missed out entirely — the vaccine simply did not exist when they were young enough to receive it.

Unlike infants, this cohort was never offered a catch-up vaccination programme. As a result, thousands of young adults have entered higher education without any protection against MenB, many of them completely unaware of this vulnerability.

Teenagers in the UK are currently offered the MenACWY vaccine through the NHS, which guards against four other strains of meningitis. However, this provides no defence against the B strain — the very one driving the current outbreak.

A Family's Devastating Loss

The consequences of this gap have been made painfully clear by the story of Meg Draper, a university student who died last October after contracting Meningitis B.

Her parents, Helen and Lee, have since spoken out publicly, urging the government to improve communication around the limitations of standard NHS meningitis vaccines.

Helen recalled the early warning signs: "Megan had called us on the Friday night to say she was feeling a bit lethargic and she didn't really want to go out that evening. That rang alarm bells with us because Megan always wanted to go out and socialise."

By the following afternoon, Meg's condition had rapidly deteriorated. A rash had spread across her body, her limbs ached, and she felt severely unwell. Despite seeking medical help, she did not survive.

Lee Draper placed part of the blame on poor public awareness: "We assumed that Megan had had a meningitis vaccination and to us, we sent her off to university thinking that. It was after we knew what strain she had, meningitis B, that she wasn't vaccinated against that — and we had no idea that she didn't have protection against that."

The couple said they would have paid the £220 private vaccination cost without hesitation had they known the risk.

The Government's Response and Emergency Action

In direct response to the Kent outbreak, a targeted vaccination programme has been launched, initially focused on students residing in halls of residence at the University of Kent's Canterbury Campus. Health authorities have indicated the programme could be extended further, depending on ongoing risk assessments by the UK Health Security Agency.

In the meantime, officials are urging anyone offered preventative antibiotics to come forward promptly, describing this as the most effective immediate measure for limiting the spread of disease.

Health Secretary Wes Streeting has instructed independent advisors to revisit the eligibility criteria for meningitis vaccines across the UK. Addressing Parliament, he said: "In light of this latest outbreak, I will be asking them to re-examine eligibility for meningitis vaccines. I will do so without prejudicing their decision because we have to follow the clinical advice on this."

Why Vaccinating Teenagers Against MenB Is More Complex Than It Sounds

Public health experts caution that expanding MenB vaccination to older age groups is not a straightforward decision.

Professor Sir Andrew Pollard, an immunologist at the University of Oxford, explained that while the vaccine performs well in infants, its effectiveness in teenagers and young adults is less clear-cut. He noted that MenB is not a single uniform strain but rather an umbrella term covering a wide variety of bacterial subtypes. The vaccine is formulated to target as many of these as possible, but it cannot cover all of them.

"The B strain is more complicated because although we call it the B strain, it's actually a collection of a very large number of different strains, some of which are covered by the B vaccine and some aren't," he told the BBC.

Adding further complexity is the fact that some individuals carry MenB bacteria in their nose or throat without ever becoming ill themselves. These asymptomatic carriers can unknowingly transmit the bacteria to others who may not be so fortunate.

Who Is Most at Risk?

Meningitis B can affect anyone, but certain groups face a significantly higher risk. Babies and children under five are most vulnerable, followed closely by teenagers and young adults between the ages of 15 and 24 — precisely the demographic now at the centre of the Kent outbreak.

As pressure mounts on the government, many parents are already opting to have their children vaccinated privately at a cost of around £220. Whether a broader national programme will follow remains to be seen, but this outbreak has made one thing unmistakably clear: the current approach to MenB protection among young people is in urgent need of review.